SCHEMBL17847402

SCHEMBL17847402

CCOCOc1ccc(C(=N)NO)cc1C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
RARA P10276 1/20 0.33
RARB P10826 1/20 0.33
RARG P13631 1/20 0.33
KDM4E B2RXH2 5/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 3/20 0.33
ALDH1A1 P00352 3/20 0.33
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
HDAC1 Q13547 2/20 0.32
HDAC8 Q9BY41 2/20 0.32
HDAC6 Q9UBN7 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPK1 P28482 2/20 0.32
HTT P42858 1/20 0.32
PRSS1 P07477 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17847407 0.76 PTGDR2 (0.57) PTGDR2KDM4ESMN1; SMN2LMNAALDH1A1
SCHEMBL6902107 0.74 ALDH1A1 (0.40) PTGDR2KDM4ESMN1; SMN2LMNAALDH1A1
SCHEMBL17847388 0.73 PTGDR (0.41) PTGDR2RARARARBRARGALDH1A1
SCHEMBL3181105 0.72 POLB (0.50) KDM4ESMN1; SMN2LMNAALDH1A1TP53
SCHEMBL23588051 0.71 THRA (0.52) THRATHRBSMN1; SMN2LMNAMEN1
SCHEMBL17847396 0.71 TRPV4 (0.43) PTGDR2LMNAMAPK1HTT
SCHEMBL19411800 0.69 THRA (0.58) THRATHRB
SCHEMBL13139482 0.69 THRA (0.58) THRATHRB
SCHEMBL20116603 0.69 TSHR (0.60) KDM4ESMN1; SMN2ALDH1A1TP53MAPT
SCHEMBL19317270 0.69 PRSS1 (0.37) KDM4ESMN1; SMN2LMNAALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107250115-B Compounds, synthesis method thereof and application thereof in medicines and cosmetics 盖尔德马研究及发展公司 2021-11-05 CN disclosed
EP-3233806-B1 HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS GALDERMA RES & DEV (FR) 2021-10-27 EP disclosed
US-10647688-B2 Compounds, synthesis method thereof and use of same in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2020-05-12 US disclosed
US-20170342040-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2017-11-30 US disclosed
EP-3233806-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2017-10-25 EP disclosed
WO-2016097626-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342040-A1 NOVEL COMPOUNDS, SYNTHESIS METHOD THEREOF AND USE OF SAME IN MEDICINE AND IN COSMETICS RARA, RARB, RARG THRA 1036/4885THRB 1975/4885PTGDR2 225/4885
US-10647688-B2 Compounds, synthesis method thereof and use of same in medicine and in cosmetics RARA, RARB, RARG THRA 1156/4885THRB 2147/4885PTGDR2 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.